This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
ASCO 2024: Post-Progression Survival of Patients with mHSPC Who Received Darolutamide or Placebo: Post Hoc Analysis of ARASENS
June 2, 2024
ASCO 2024: ctDNA Fraction as a Predictor of Treatment Efficacy in a Randomized Phase 2 Trial of [177Lu] Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing After Docetaxel
June 2, 2024
ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Cisplatin-Eligible Population from EV-302/KEYNOTE-A39
June 2, 2024
ASCO 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Patients with Low Tumor Burden
June 2, 2024
ASCO 2024: ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer
June 2, 2024
ASCO 2024: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
June 2, 2024
ASCO 2024: Rapid and Deep Prostate-Specific Antigen Response to Apalutamide plus ADT and Survival in Metastatic Castration-Sensitive Prostate Cancer in Real World Practice in the US (OASIS Project)
June 2, 2024
ASCO 2024: First-Line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma (RCC): An International Multi-Center Study
June 2, 2024
ASCO 2024: Prognostic Validation of a Digital Pathology-Based Multi-Modal Artificial Intelligence Biomarker in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the CHAARTED Trial (ECOG-ACRIN EA3805)
June 2, 2024
ASCO 2024: COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy
June 2, 2024
ASCO 2024: Study EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC) 2-Year Event-Free Survival and Safety Data for Cohort H
June 2, 2024
ASCO 2024: Association of Machine Learning–derived Histological Features with Transcriptomic Molecular Subtypes in Advanced Renal Cell Carcinoma
June 2, 2024
ASCO 2024: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Analysis of the Cisplatin-Ineligible Population from EV-302/KEYNOTE-A39
June 2, 2024
ASCO 2024: Long Term Cardiovascular Adverse Outcomes in Testicular Cancer Survivors: Real-World U.S. Population-Based Study
June 2, 2024
ASCO 2024: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM/Alliance A032101)
June 2, 2024
ASCO 2024: Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
June 2, 2024
ASCO 2024: Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + Enzalutamide as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
June 2, 2024
ASCO 2024: Comparison of TKI and CPI Strategies as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: Real-World Outcome Data from the German Research Platform CARAT
June 2, 2024
ASCO 2024: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2
June 2, 2024
ASCO 2024: 68Ga-PSMA PET/CT Response and Clinical Outcomes in Patients Treated with Enzalutamide as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer: Results of a Prospective Study
June 2, 2024
Page 7 of 575
Start
Prev
2
3
4
5
6
7
8
9
10
11
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free